1. Home
  2. CPHI vs HBIO Comparison

CPHI vs HBIO Comparison

Compare CPHI & HBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo China Pharma Holdings Inc.

CPHI

China Pharma Holdings Inc.

N/A

Current Price

$0.52

Market Cap

25.3M

Sector

Health Care

ML Signal

N/A

Logo Harvard Bioscience Inc.

HBIO

Harvard Bioscience Inc.

N/A

Current Price

$9.50

Market Cap

26.5M

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
CPHI
HBIO
Founded
N/A
1901
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Laboratory Analytical Instruments
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
25.3M
26.5M
IPO Year
2008
2000

Fundamental Metrics

Financial Performance
Metric
CPHI
HBIO
Price
$0.52
$9.50
Analyst Decision
Hold
Analyst Count
0
2
Target Price
N/A
★ $11.50
AVG Volume (30 Days)
★ 98.2K
26.4K
Earning Date
11-24-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
$4,144,268.00
★ $116,176,000.00
Revenue This Year
N/A
$4.09
Revenue Next Year
N/A
$5.22
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.38
$0.40
52 Week High
$19.19
$10.20

Technical Indicators

Market Signals
Indicator
CPHI
HBIO
Relative Strength Index (RSI) 35.22 66.51
Support Level $0.38 $8.01
Resistance Level $0.68 N/A
Average True Range (ATR) 0.06 0.51
MACD -0.00 0.09
Stochastic Oscillator 9.00 66.51

Price Performance

Historical Comparison
CPHI
HBIO

About CPHI China Pharma Holdings Inc.

China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.

About HBIO Harvard Bioscience Inc.

Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.

Share on Social Networks: